Following expert medical advice, the UK government has implemented an indefinite ban on puberty blockers for under-18s with gender dysphoria, except within clinical trials. This decision, supported by the Commission on Human Medicines citing unacceptable safety risks, makes permanent the emergency measures initially introduced in May. The ban applies UK-wide, following consultation with devolved administrations, and affects new patients only; existing patients will continue treatment. A planned clinical trial aims to establish a clearer evidence base for the medication’s use.
Read More
A federal appeals court has upheld an Indiana law banning puberty blockers and hormones for transgender children under 18, mirroring similar legislation passed in other Republican-led states. The court rejected arguments that the law discriminates based on sex or violates parental rights, concluding that the law applies equally to all minors and that parents do not have an unfettered right to any medical treatment for their children. This decision aligns with rulings in other states and sets the stage for the Supreme Court to potentially decide the fate of such laws nationwide, with proponents arguing they protect children from experimental treatments and opponents citing the positive mental health outcomes associated with these treatments.
Read More
John Q. Hosedrinker